Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company with 6 novel non-opioid products in development to treat pain, both in the U.S. and around the world.
The prevalence of pain in the US reached 178 million adults in 20141 and many patients experiencing moderate to severe pain receive prescription opioids. In 2018, 9.9 million people misused prescription opioid pain relievers2. Prescription opioids are implicated in 36% of all emergency department visits in the US3, and 46 people die every day from prescription opioid overdoses.4
Neumentum’s product candidates have the potential to provide the benefits of safe and effective pain management without the risks for abuse and misuse that come with opioids, or opioid induced side effects including potentially life-threatening respiratory depression. Neumentum’s pipeline offers a diverse range of product candidates, which if successful, will offer patients, providers and payers new alternatives to opioids for the treatment of acute and chronic pain in the hospital and community settings.